Importantly, the effects of co-treatment with AD AEVs and only Factor I, which can degrade specific complement effectors only when aided by co-factors (e.g., Factor H and CR1) [8], were not different from the effects of AD AEVs alone (AD vs. AD plus Factor I, p = 0.349; AD plus Factor I vs. Normal AEVs, p = 0.053). This evidence concerns the gene CR1 and Alzheimer disease.